Skip to main content
Log in

Clonal Hematopoiesis of Indeterminate Potential: an Expanding Genetic Cause of Cardiovascular Disease

  • Genetics and Genomics (A. Marian, Section Editor)
  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Clonal hematopoiesis of indeterminate potential (CHIP) is a novel cardiovascular risk factor that develops as aging hematopoietic stem cells (HSCs) acquire somatic mutations which confer a clonal survival advantage in their progeny. These cells confer increased leukemogenic risk but confer a greater absolute risk of cardiovascular disease—which appears to be mediated through altered inflammatory pathways. Here we review the evidence the risk of cardiovascular disease conferred by CHIP. We also review the evidence regarding risk factors associated with CHIP.

Recent Findings

The most recent evidence suggests that CHIP is associated with increased cardiovascular risk beyond atherosclerosis, which has been established in multiple studies, but also in heart failure and aortic valve stenosis. Additionally, the list of conditions associated with CHIP continues to grow including germline genetics, smoking, cancer therapies, radiation exposure, premature menopause, and unhealthy diet.

Summary

CHIP is a cardiovascular risk factor of increasingly recognized importance, and new data continues to emerge about the risks it confers, which will need more prospective validation. Although risk factors for CHIP are being identified, relatively little is known about the mechanisms by which CHIP develops, which requires further study.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Jaiswal S, Natarajan P, Silver AJ, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017;377:111–21.

    Article  Google Scholar 

  2. Natarajan P, Jaiswal S, Kathiresan S. Clonal hematopoiesis: somatic mutations in blood cells and atherosclerosis. Circ Genom Precis Med. 2018;11:e001926.

    Article  CAS  Google Scholar 

  3. •• Bick AG, Weinstock JS, Nandakumar SK, et al. Inherited causes of clonal hematopoiesis of indeterminate potential in TOPMed whole genomes. Nature. 2020;586:763–8. This study suggested that there is only modest heritability of CHIP, and that life exposures may be central to its development.

    Article  CAS  Google Scholar 

  4. Genovese G, Kahler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014;371:2477–87.

    Article  Google Scholar 

  5. Zink F, Stacey SN, Norddahl GL, et al. Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly. Blood. 2017;130:742–52.

    Article  CAS  Google Scholar 

  6. Xie M, Lu C, Wang J, et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med. 2014;20:1472–8.

    Article  CAS  Google Scholar 

  7. Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371:2488–98.

    Article  Google Scholar 

  8. Fuster JJ, MacLauchlan S, Zuriaga MA, et al. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science. 2017;355:842–7.

    Article  CAS  Google Scholar 

  9. Wang W, Liu W, Fidler T, et al. Macrophage inflammation, erythrophagocytosis, and accelerated atherosclerosis in Jak2 (V617F) mice. Circ Res. 2018;123:e35–47.

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Bick AG, Pirruccello JP, Griffin GK, et al. Genetic interleukin 6 signaling deficiency attenuates cardiovascular risk in clonal hematopoiesis. Circulation. 2020;141:124–31.

    Article  CAS  Google Scholar 

  11. Dorsheimer L, Assmus B, Rasper T, et al. Association of mutations contributing to clonal hematopoiesis with prognosis in chronic ischemic heart failure. JAMA Cardiol. 2019;4:25–33.

    Article  Google Scholar 

  12. Cremer S, Kirschbaum K, Berkowitsch A, et al. Multiple somatic mutations for clonal hematopoiesis are associated with increased mortality in patients with chronic heart failure. Circ Genom Precis Med. 2020;13:e003003.

    Article  Google Scholar 

  13. Assmus B, Cremer S, Kirschbaum K, et al. Clonal haematopoiesis in chronic ischaemic heart failure: prognostic role of clone size for DNMT3A- and TET2-driver gene mutations. Eur Heart J. 2021;42:257–65.

    Article  CAS  Google Scholar 

  14. Kiefer KC, Cremer S, Pardali E, et al. Full spectrum of clonal haematopoiesis-driver mutations in chronic heart failure and their associations with mortality. ESC Heart Fail. 2021;8:1873–84.

    Article  Google Scholar 

  15. Sano S, Oshima K, Wang Y, Katanasaka Y, Sano M, Walsh K. CRISPR-mediated gene editing to assess the roles of Tet2 and Dnmt3a in clonal hematopoiesis and cardiovascular disease. Circ Res. 2018;123:335–41.

    Article  CAS  Google Scholar 

  16. Mas-Peiro S, Hoffmann J, Fichtlscherer S, et al. Clonal haematopoiesis in patients with degenerative aortic valve stenosis undergoing transcatheter aortic valve implantation. Eur Heart J. 2020;41:933–9.

    Article  CAS  Google Scholar 

  17. Abplanalp WT, Mas-Peiro S, Cremer S, John D, Dimmeler S, Zeiher AM. Association of clonal hematopoiesis of indeterminate potential with inflammatory gene expression in patients with severe degenerative aortic valve stenosis or chronic postischemic heart failure. JAMA Cardiol. 2020;5:1–6.

    Article  Google Scholar 

  18. Silver AJ, Bick AG, Savona MR. Germline risk of clonal haematopoiesis. Nat Rev Genet. 2021;22(9):603–17. https://doi.org/10.1038/s41576-021-00356-6.

    Article  CAS  PubMed  Google Scholar 

  19. Hinds DA, Barnholt KE, Mesa RA, et al. Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms. Blood. 2016;128:1121–8.

    Article  CAS  Google Scholar 

  20. Dawoud AAZ, Tapper WJ, Cross NCP. Clonal myelopoiesis in the UK Biobank cohort: ASXL1 mutations are strongly associated with smoking. Leukemia. 2020;34:2660–72.

    Article  CAS  Google Scholar 

  21. Coombs CC, Zehir A, Devlin SM, et al. Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes. Cell Stem Cell. 2017;21:374-82.e4.

    Article  CAS  Google Scholar 

  22. Haring B, Reiner AP, Liu J, et al. Healthy lifestyle and clonal hematopoiesis of indeterminate potential: results from the women’s health initiative. J Am Heart Assoc. 2021;10:e018789.

    Article  CAS  Google Scholar 

  23. Honigberg MC, Zekavat SM, Niroula A, et al. Premature menopause, clonal hematopoiesis, and coronary artery disease in postmenopausal women. Circulation. 2021;143:410–23.

    Article  Google Scholar 

  24. •• Bolton KL, Ptashkin RN, Gao T, et al. Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nat Genet. 2020;52:1219–26. Findings from this study showed that different cancer therapies help to select for specific clones in CHIP, and also provides further evidence that cigarette smoking is related to CHIP.

    Article  CAS  Google Scholar 

  25. Boucai L, Falcone J, Ukena J, et al. Radioactive iodine-related clonal hematopoiesis in thyroid cancer is common and associated with decreased survival. J Clin Endocrinol Metab. 2018;103:4216–23.

    Article  Google Scholar 

  26. Anthony KM MJ, Jaiswal S, Natarajan P, Desai P, Hayden KM, Bick AG, Carty CL, Collins JM, Love S, Stewart J, Schwartz G, Reiner A, Whitsel EA. Radon is associated with clonal hematopoiesis of indeterminate potential in the women’s health initiative. AHA Scientific Sessions; 2020 15 Dec 2020: Circulation.

  27. Garrett-Bakelman FE, Darshi M, Green SJ, et al. The NASA Twins Study: a multidimensional analysis of a year-long human spaceflight. Science. 2019;364(6436):eaau8650. https://doi.org/10.1126/science.aau8650.

  28. Mencia-Trinchant N, MacKay MJ, Chin C, et al. Clonal hematopoiesis before, during, and after human spaceflight. Cell Rep. 2021;34:108740.

    Article  CAS  Google Scholar 

  29. • Bhattacharya R, Zekavat SM, Uddin MM, et al. Association of diet quality with prevalence of clonal hematopoiesis and adverse cardiovascular events. JAMA Cardiol. 2021:e211678. https://doi.org/10.1001/jamacardio.2021.1678Findings from this paper established an association between unhealthy dietary pattern low in fruits and vegetables and high in red meats as associated with CHIP.

  30. Cimmino L, Dolgalev I, Wang Y, et al. Restoration of TET2 function blocks aberrant self-renewal and leukemia progression. Cell. 2017;170:1079-95.e20.

    Article  CAS  Google Scholar 

  31. Heyde A, Rohde D, McAlpine CS, et al. Increased stem cell proliferation in atherosclerosis accelerates clonal hematopoiesis. Cell. 2021;184:1348-61.e22.

    Article  CAS  Google Scholar 

  32. van Deuren RC, Andersson-Assarsson JC, Kristensson FM, et al. Clone expansion of mutation-driven clonal hematopoiesis is associated with aging and metabolic dysfunction in individuals with obesity. bioRxiv 2021:2021.05.12.443095.

  33. Lusis AJ. A vicious cycle in atherosclerosis. Cell. 2021;184:1139–41.

    Article  CAS  Google Scholar 

  34. Sánchez-Cabo F, Fuster JJ. Clonal haematopoiesis and atherosclerosis: a chicken or egg question? Nat Rev Cardiol. 2021;18(7):463–4. https://doi.org/10.1038/s41569-021-00554-z.

    Article  CAS  PubMed  Google Scholar 

  35. Libby P, Sidlow R, Lin AE, et al. Clonal Hematopoiesis. J Am Coll Cardiol. 2019;74:567–77.

    Article  Google Scholar 

  36. Sidlow R, Lin AE, Gupta D, et al. The clinical challenge of clonal hematopoiesis, a newly recognized cardiovascular risk factor. JAMA Cardiol. 2020;5:958–61.

    Article  Google Scholar 

  37. Swirski FK. Inflammation and CVD in 2017: From clonal haematopoiesis to the CANTOS trial. Nat Rev Cardiol. 2018;15:79–80.

    Article  Google Scholar 

  38. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119–31.

    Article  CAS  Google Scholar 

  39. Tardif JC, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381:2497–505.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Alexander G. Bick.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Genetics and Genomics

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bhattacharya, R., Bick, A.G. Clonal Hematopoiesis of Indeterminate Potential: an Expanding Genetic Cause of Cardiovascular Disease. Curr Atheroscler Rep 23, 66 (2021). https://doi.org/10.1007/s11883-021-00966-9

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s11883-021-00966-9

Keywords

Navigation